08th - 10th October, 2019, Boston (USA)

19th Pharmacovigilance 2019

19th Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting Pv development. 

CONFERENCE INTRODUCTION:
U.S. Pharmacovigilance showcase estimate was esteemed over USD 1 billion of every 2015, and anticipated to witness 10.7% CAGR from 2016 to 2024 to outperform USD 2.5 billion by 2024. The global pharmacovigilance (PV) & drug safety software market size was estimated at USD 124.6 million in 2016 and is expected to exhibit a CAGR of 6.5% over the forecast period. Increasing incidence of adverse drug reactions (ADR) are expected to propel the demand for pharmacovigilance (PV) software in the coming years. Increasing death rates attributable to antagonistic medication occasions and emerging patient concerns relating to wellbeing and viability of medications will drive industry development. Global Pharmacovigilance Market expected to Reach US$6.1 bn by 2020 expanding at a CAGR of 14.2% from 2015 to 2020 and also expected to reach a market size of $8.23 billion by 2022. By 2020, the size of the global pharmaceutical market is anticipated to grow to USD 1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey. The rapid induction in the market throws up the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base.

19th Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry. The entire program will cover the detection, analysis and prevention of adverse drug reactions. It will be studied with the help of case studies and industry experiences. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting Pv development. What does the future hold for pv? Find out at this conference on opportunities and activities shaping pv to 2020 with respect to regulations, technologies and services. Learn and know on what are drug producers and service providers doing? What regulations and technologies influence the current PV field? You can also discover at 19th Pharmacovigilance 2019 on spending forecasts for PV (US, the EU and Asia).

KEY THEMES DISCUSSED IN THIS CONFERENCE:

•    Pharmacovigilance in the US: What comes next for the industry?
•    Recent developments - legislation, policies, systems, technology, communication strategies and best practice in PV
•    Challenges and Opportunities for Effective Pharmacovigilance in the 21st Century 
•    Why does pharmacovigilance sometimes fail and where could the fault lie?
•    Pharmacovigilance and healthcare system
•    Future of Signal Detection - Growing companies and safety efficiencies
•    Technology Impact - Cloud – Big data – Analytics – AI – Machine learning
•    Good Clinical Practices and Good Pharmacovigilance practices
•    Future of outsourced phase I, II and III trials and post-marketing studies, 
•    Data quality management and analysis – analyzing the new guidelines
•    Strategies to improve clinical trials and PV
•    Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
•    Patient centric approach to help improve patient safety
•    Outsourcing activities - Choosing your right vendor and setting the path right
•    PV Audit & inspections - preparation, implementation and lessons to be learnt
•    Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
•    Current regulations and guidelines - USA, EU and RoW
•    The developing regulatory framework in advanced and developing markets 
•    Be part of a major networking opportunity

WHO SHOULD ATTEND:
CEO’s, CTO’s, CIO’s, Presidents, VPs, Directors, Heads, Managers, Scientific Advisors, Consultants of:
• Pharmacovigilance 
• Pharmacoepidemiology 
• Pharmacogenomics 
• Drug/Product Safety 
• Drug Development 
• Information and Clinical Data Management 
• Clinical Pharmacology 
• Clinical Safety 
• Periodical safety update Reports 
• Risk Management 
• Research & Development 
• Quality Assurance 
• Patient Safety 
• Signal Detection 
• Safety Surveillance 
• Outcomes Research 
• Data Analysis 
• Epidemiology 
• Medical Affairs 
• Regulatory Affairs and Compliance 
• Information technology 
• Sales and Marketing 

WHY SHOULD YOU ATTEND? 
19th Pharmacovigilance 2019 – “Uniting “Ensuring safer drugs to market by analyzing latest developments in pharmacovigilance, drug safety and risk management"
Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway.  Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.

For more details: https://www.virtueinsight.com/pharma/19th-Pharmacovigilance-2019/

Share this post

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedIn